[
  {
    "ts": null,
    "headline": "Pfizer Inc. (NYSE:PFE) is largely controlled by institutional shareholders who own 68% of the company",
    "summary": "Key Insights Significantly high institutional ownership implies Pfizer's stock price is sensitive to their trading...",
    "url": "https://finnhub.io/api/news?id=c6b04d2a646a06a7138eb9769e691003389cdc7cb81d589ce49a9241a8690457",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736431211,
      "headline": "Pfizer Inc. (NYSE:PFE) is largely controlled by institutional shareholders who own 68% of the company",
      "id": 132352697,
      "image": "https://media.zenfs.com/en/simply_wall_st__316/8f018d189c2c443014c49845310ae091",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Key Insights Significantly high institutional ownership implies Pfizer's stock price is sensitive to their trading...",
      "url": "https://finnhub.io/api/news?id=c6b04d2a646a06a7138eb9769e691003389cdc7cb81d589ce49a9241a8690457"
    }
  },
  {
    "ts": null,
    "headline": "Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.",
    "summary": "Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second presidency.",
    "url": "https://finnhub.io/api/news?id=0622b5dd71ba4d46b5d12049e3d283a02a5e7da194b12486ae101a4795827d78",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736427603,
      "headline": "Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.",
      "id": 132349387,
      "image": "https://media.zenfs.com/en/ibd.com/e1eeaef96933bc3e739bae513ec3f5e4",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second presidency.",
      "url": "https://finnhub.io/api/news?id=0622b5dd71ba4d46b5d12049e3d283a02a5e7da194b12486ae101a4795827d78"
    }
  },
  {
    "ts": null,
    "headline": "Buy The Dip: SCHD's Top Holdings Show That It Is Way Too Cheap",
    "summary": "Discover why SCHD is a clear buy with a look at its top 10 holdings and why they make it an attractive investment opportunity right now.",
    "url": "https://finnhub.io/api/news?id=3b68bfa866454efa7af7ce3949bd40eddda968966891067ff52185ad91becf1d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736424000,
      "headline": "Buy The Dip: SCHD's Top Holdings Show That It Is Way Too Cheap",
      "id": 132349330,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1289941019/image_1289941019.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Discover why SCHD is a clear buy with a look at its top 10 holdings and why they make it an attractive investment opportunity right now.",
      "url": "https://finnhub.io/api/news?id=3b68bfa866454efa7af7ce3949bd40eddda968966891067ff52185ad91becf1d"
    }
  },
  {
    "ts": null,
    "headline": "Nurix Therapeutics: Speculative Bet On BTK Degraders And Targeted Protein Modulation",
    "summary": "Nurix Therapeutics (NRIX) leads in targeted protein modulation with its DELigase platform, developing BTK degraders like NX-5948.",
    "url": "https://finnhub.io/api/news?id=9f06a73ba77a30ccbaa704beaa0d91ca5181cad64d94592e296ca168a2816bc9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736412292,
      "headline": "Nurix Therapeutics: Speculative Bet On BTK Degraders And Targeted Protein Modulation",
      "id": 132347250,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2152092840/image_2152092840.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Nurix Therapeutics (NRIX) leads in targeted protein modulation with its DELigase platform, developing BTK degraders like NX-5948.",
      "url": "https://finnhub.io/api/news?id=9f06a73ba77a30ccbaa704beaa0d91ca5181cad64d94592e296ca168a2816bc9"
    }
  },
  {
    "ts": null,
    "headline": "Buy 6 'Safer' Dividend Dogs Of 23 January Barron's Better Bets Than T-Bills",
    "summary": "Six of the top ten BBB Dogs are ideally priced, with dividends from $1K invested exceeding single share prices. Read more to see my picks.",
    "url": "https://finnhub.io/api/news?id=d20bcaa7ff495ceaaab28ed210083996d5a7bd34145d1296e18a40d15592d3e1",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736404100,
      "headline": "Buy 6 'Safer' Dividend Dogs Of 23 January Barron's Better Bets Than T-Bills",
      "id": 132346430,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/512187837/image_512187837.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Six of the top ten BBB Dogs are ideally priced, with dividends from $1K invested exceeding single share prices. Read more to see my picks.",
      "url": "https://finnhub.io/api/news?id=d20bcaa7ff495ceaaab28ed210083996d5a7bd34145d1296e18a40d15592d3e1"
    }
  }
]